{"id":"gfh375","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K delta subunit, GFH375 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.","oneSentence":"GFH375 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:20.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07259590","phase":"PHASE1, PHASE2","title":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-10-21","conditions":"Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)","enrollment":126},{"nctId":"NCT06500676","phase":"PHASE1, PHASE2","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","status":"RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2024-07-09","conditions":"KRAS G12D Mutations, Advanced Solid Tumors","enrollment":407},{"nctId":"NCT07026916","phase":"PHASE2","title":"A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GFH375","genericName":"GFH375","companyName":"Genfleet Therapeutics (Shanghai) Inc.","companyId":"genfleet-therapeutics-shanghai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GFH375 is a small molecule inhibitor of the PI3K delta subunit. Used for Moderate to severe ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}